Filing Flows › NovoCure (NVCR) › Q3 2025
NovoCure (NVCR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
NovoCure (NVCR) reported revenue of $167M for the third quarter 2025 (Q3 2025), +8% from a year earlier and +5% from the quarter before. Operating margin was -21.5%, net loss $37.3M (22.3% of revenue).
NovoCure, Q3 2025: revenue $167M (+8% year over year), operating margin -21.5%, net loss $37.3M, operating cash flow $20.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $167M | +5% | +8% |
| Operating profit | −$36.0M | — | — |
| Net earnings | −$37.3M | — | — |
| Operating cash flow | $20.6M | — | +98% |
| Free cash flow | $14.9M | — | — |
What changed
Revenue was $167.2M in Q3 2025, up 8% year over year and up 5% from the previous quarter.
Gross margin was 73.2%, down 3.9 points from a year earlier. Operating costs exceeded revenue by $36.0M, an operating margin of -21.5%. Operating expenses grew 4% against revenue growth of 8%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $37.3M, narrower than the previous quarter's $40.1M loss.
Operating cash flow was $20.6M (up 98% year over year). Non-cash charges added back $3.7M of depreciation and amortization and $29.3M of share-based compensation. Working capital and other items added $24.9M. Capital expenditures of $5.7M left free cash flow of $14.9M.
Questions
What was NovoCure's revenue in the third quarter 2025?
NovoCure (NVCR) reported revenue of $167M for the third quarter 2025 (Q3 2025), +8% from a year earlier and +5% from the quarter before.
Was NovoCure profitable in the third quarter 2025?
Operating loss was $36.0M (-21.5% of revenue) and net loss $37.3M.
Source: NovoCure 10-Q on SEC EDGAR.